Onxeo is focused on the development of the next generation of DNA damage repair inhibitors from its novel oligonucleotide platON platform. The lead asset, AsiDNA, belongs to the same class of drugs as PARP inhibitors, but has a different mechanism of action. AsiDNA is in a Phase Ib trial in combination with chemotherapy in solid tumours; preliminary results are expected by end-2019, which is within the existing cash reach to Q320. To reflect the progress Onxeo has made with AsiDNA we have inc
16 Sep 2019
Onxeo - Next generation of DNA damage repair inhibitors
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Onxeo - Next generation of DNA damage repair inhibitors
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
16 Sep 2019 -
Author:
Dr Jonas Peciulis -
Pages:
24
Onxeo is focused on the development of the next generation of DNA damage repair inhibitors from its novel oligonucleotide platON platform. The lead asset, AsiDNA, belongs to the same class of drugs as PARP inhibitors, but has a different mechanism of action. AsiDNA is in a Phase Ib trial in combination with chemotherapy in solid tumours; preliminary results are expected by end-2019, which is within the existing cash reach to Q320. To reflect the progress Onxeo has made with AsiDNA we have inc